Hormone Replacement (Therapy): A Time for Interrogation, Information and Further Studies

  • O. Markowitz
  • C. Meynant
  • P. Bouchard
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 46)

Abstract

The treatment of menopause relies mainly upon the use of estrogens to alleviate climacteric symptoms, increase bone mass, and consequently, potentially improve quality of life. Although a great deal of experimental data supports the beneficial effects of estrogen treatments on (arterial) cardiovascular prevention and brain function, it was recently discovered that some of the doses used, as well as certain routes of administration or different combinations with varying forms and doses of progestins, could increase the risk of cardiovas-cular events, breast cancer, and even dementia. The current literature clearly demonstrates the major controversy of administering hormone replacement therapy to women with increased risk of breast cancer and arterial cardiovascular complications because of their age notwithstanding the further risk due to some comorbid risk factors such as diabetes, high blood pressure, hyperlipidemia, etc. At this stage in our knowledge, a profound gap still exists between our hope, experimental information, and evidence-based medicine. Until this gap is closed or corrected, physicians must be very critical in their use of Hormone Replacement (HR), and use minimal doses in selected volunteer women that demand such a treatment to alleviate symptoms.

Keywords

Placebo Estrogen Osteoporosis Dementia Estrogen Antagonist 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. In: HOPE (Women’s Health, Osteoporosis, Progestin, Estrogen trial). Fertil Steril 75:1080–1087Google Scholar
  2. Barrett-Connor E, Slone S, Greendale G et al. (1997) The Postmenopausal Estrogen/Progestin Interventions Study: (PEPI) primary outcomes in adherent women. Maturitas 27:261–274CrossRefPubMedGoogle Scholar
  3. Barrett-Connor E, Grady D, Sashegyi A et al., for the MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–857CrossRefPubMedGoogle Scholar
  4. Cauley JA, Norton L, Lippman ME et al. (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation (erratum appears in Breast Cancer Res Treat 67:191). Breast Cancer Res Treat 65:125–134CrossRefPubMedGoogle Scholar
  5. Cherry N, Gilmour K, Hannaford A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H, Esprit Team (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 360:2001–2008CrossRefPubMedGoogle Scholar
  6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, for the WHI Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253Google Scholar
  7. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofied PM (2002) A study of HRT in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 109(9): 1056–1062CrossRefPubMedGoogle Scholar
  8. Clarkson TB (2002) The new conundrum: do estrogens have any cardiovascular benefits. Int J Fertil 47(2):61–68Google Scholar
  9. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589–1593CrossRefPubMedGoogle Scholar
  10. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  11. Grady D, Herrington D, Bittner V et al., for the HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57CrossRefPubMedGoogle Scholar
  12. Greendale GA, Wells B, Marcus R, Barrett-Connor E, for the Postmenopausal Estrogen/Progestin Interventions Trial Investigators (2000) How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions trial. Arch Intern Med 160:3065–3071CrossRefPubMedGoogle Scholar
  13. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E, for the PEPI Safety Follow-up Study (PSFS) Investigators (2002) Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study. Arch Intern Med 162:665–672CrossRefPubMedGoogle Scholar
  14. Grodstein F, Clarkson TB, Manson JE (2003) Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 348:645–650CrossRefPubMedGoogle Scholar
  15. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Ara-gaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, The Women’s Health Initiative Investigators (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839–1854Google Scholar
  16. Herrington DM, Reboussin DM, Brosnihan KB et al. (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. In: ERA (Estrogen Replacement and Atherosclerosis trial). N Engl J Med 343:522–529CrossRefGoogle Scholar
  17. Herrington DM, Vittinghoff E, Lin F et al., for the HERS Study Group (2002) Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105:2962–2967CrossRefPubMedGoogle Scholar
  18. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen ML, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254–3263CrossRefPubMedGoogle Scholar
  19. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287: 2668–2676CrossRefPubMedGoogle Scholar
  20. Lobo RA, Bush T, Carr BR, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. FertilSteril 76:13–24CrossRefPubMedGoogle Scholar
  21. Mendelsohn ME, Bkana RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801–1811CrossRefPubMedGoogle Scholar
  22. Mikkola TS, Clarkson TB (2002) Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 52:605–619CrossRefGoogle Scholar
  23. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L (2001) Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76:25–31CrossRefPubMedGoogle Scholar
  24. Resnick SM, Henderson VW (2002) Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 288(17):2170–2172CrossRefPubMedGoogle Scholar
  25. Scarabin PY, Oger E, Plu-Bureau G, and the Estrogen and Thromboembolism Risk (ESTHER) Study group (2003) Oral but not transdermal Estrogen Replacement Therapy is associated with venous thromboembolism. Lancet (in press)Google Scholar
  26. Shumaker SA, Legault C, Rapp SR, Thai L, Wallace RB, Ockene JK, Hen-drix SL, Jones III BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Watctawski-Wende J, for the WHIMS Investigators (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 287:2651–2662CrossRefGoogle Scholar
  27. Solomon CG, Dluhy RG (2003) Rethinking Postmenopausal Hormone Therapy. N Engl J Med 348:579–580CrossRefPubMedGoogle Scholar
  28. Stampfer MO, Colditz GA (2002) Estrogen Replacement Therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Ann Intern Med 137:290CrossRefGoogle Scholar
  29. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estro-gen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (erratum appears in JAMA 1995; 274:1676). JAMA 273:199–208CrossRefGoogle Scholar
  30. The Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 276:1389–1396CrossRefGoogle Scholar
  31. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH (2001) Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75:1065–1079CrossRefPubMedGoogle Scholar
  32. Vickers M, Meade T, Darbyshire J (2002) WISDOM: history and early demise — was it inevitable? Climacteric 5(4):317–325PubMedGoogle Scholar
  33. Viscoli CM, Brass LM, Kernan ZN, Sarrel PM, Sussia S, Horowitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. In: WEST (Women’s Estrogen for Stroke Trial). N Engl J Med 345:1243–1249CrossRefGoogle Scholar
  34. WHI (Women’s Health Initiative) Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefGoogle Scholar
  35. Zandi P, Carlson MC, Plassman BL, Welsh-Bommer KA, Steffens DC, Breitner JCS, for the cache County Memory Study Investigators (2002) Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288:2123–2129CrossRefPubMedGoogle Scholar
  36. Zenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A, Baygani SK, Anderson PW, Moscarelli E (2002) Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol 90(11): 1204–1210CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • O. Markowitz
  • C. Meynant
  • P. Bouchard

There are no affiliations available

Personalised recommendations